ELV
Elevance Health
Health Care · Managed Health Care · US
$415.53
Data: 2026-05-15
✓ ETHICAL PASS

WEAK MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$85.6B
Total market value of the company
16.69
Reasonably valued
13.48
Based on estimated future earnings — lower means cheaper
Rev Growth
+2.6%
Year-over-year revenue change
Profit Margin
2.6%
How much profit the company keeps from each dollar of revenue
12.1%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$388.95
-6% from current price — median analyst estimate
Recommendation
BUY
Consensus view from 21 analysts covering this stock
About Elevance Health

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.

https://www.elevancehealth.com

Country: United States Employees: 96,129 Industry: Healthcare Plans
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
26.4% PASS
Debt must be below 33% of total assets
Cash Ratio
22.8% PASS
Interest-bearing cash below 33% of assets
Receivables
16.1% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Valuation
$350.70
What our model estimates this business is worth per share
-18.5%
Trading above fair value — no margin of safety
Rating
FAIR VALUE
Overall assessment combining ethics, valuation, and quality
93.8th
Ranks in the top 6% of our 13,571 screened universe
Ethical Score
77.3
Valuation Score
71.5
Quality Score
46.3
Combined
67.6

Trading at $394, 12% above fair value of $351. Passes all ethical screens. Ranks better than 88% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

ACCUMULATION
Smart money appears to be building positions quietly
-0.198
Returns do not compensate for the risk — negative edge
-0.0192
No positive edge detected — the data suggests staying out
-0.241
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-12.1%
Historical annualised return based on price data
-50.4%
Largest peak-to-trough decline — the worst it has been
BEAR
Statistical model detects bearish conditions
Days in State
59
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

0.67
Less volatile than the market — more defensive
52W High
$412.96
-1% below the year high
52W Low
$273.71
52% above the year low
Avg Volume
1,916,969
Average daily shares traded — higher means easier to buy and sell
2.9
Days it would take all short sellers to cover — higher means more crowded
Short % Float
2.7%
Low short interest — limited bearish positioning
1.7%
Annual dividend as a percentage of the share price
$23.59
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

0.72
Moderate leverage — manageable
1.48
Adequate but worth monitoring
Quick Ratio
1.33
Like current ratio but excludes inventory — stricter test
Gross Margin
25.9%
Revenue left after cost of goods — higher means pricing power
Operating Margin
5.3%
Profit from core operations before interest and tax
$4.3B
Positive — the business generates more cash than it spends
Revenue (TTM)
$200.4B
Total revenue over the last 12 months
Net Income
$5.2B
Profitable — the bottom line is positive
Analyst Coverage
Analysts
21
Target High
$474.00
Target Median
$388.95
Target Low
$331.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

55
NEUTRAL
Mixed insider activity. 0 purchases and 0 sales in the last 90 days — no clear directional signal. Politicians have been buying this name.
Date Insider Title Type Shares Value
2026-05-19 PENCZEK RONALD W Officer 1,531 $450,579
2026-05-19 PENCZEK RONALD W Officer 1,531 $617,192
2026-05-13 HAY LEWIS III Director 563
2026-05-13 PERU RAMIRO G Director 563
2026-05-13 SCHNEIDER RYAN M. Director 563
2026-05-13 COLLIS STEVEN H Director 563
2026-05-13 STRABLE-SOETHOUT DEANNA D Director 563
2026-05-13 DEVORE SUSAN D Director 563
2026-05-13 NERI ANTONIO F Director 563
2026-05-13 JALLAL BAHIJA Director 563
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Political Trading Activity

Congressional trading disclosures involving this instrument

Date Politician Party Type Amount
2026-04-13 Ro Khanna Democrat Purchase 1K–15K
Source: Congressional disclosure filings. View all political trades at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.